Literature DB >> 9832162

Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase.

S N Murthy1, J H Wilson, T J Lukas, J Kuret, L Lorand.   

Abstract

A portion of the neurofibrillary tangles of Alzheimer's disease has the characteristics of cross-linked protein. Because the principal component of these lesions is the microtubule-associated protein tau, and because a major source of cross-linking activity within neurons is supplied by tissue transglutaminase (TGase), it has been postulated that isopeptide bond formation is a major posttranslational modification leading to the formation of insoluble neurofibrillary tangles. Here we have mapped the sites on two isoforms of human tau protein (tau23 and tau40) capable of participating in human TGase-mediated isopeptide bond formation. Using dansyl-labeled fluorescent probes, it was shown that eight Gln residues can function as amine acceptor residues, with two major sites being Gln351 and Gln424. In addition, 10 Lys residues were identified as amine donors, most of which are clustered adjacent to the microtubule-binding repeats of tau in regions known to be solvent accessible in filamentous tau. The distribution of amine donors correlated closely with that of Arg residues, suggesting a link between neighboring positive charge and the TGase selectivity for donor sites in the protein substrate. Apart from revealing the sites that can be cross-linked during the TGase-catalyzed assembly of tau filaments, the results suggest a topography for the tau monomers so assembled.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832162     DOI: 10.1046/j.1471-4159.1998.71062607.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.

Authors:  Manuela Basso; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

Review 2.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

Review 3.  Progressive supranuclear palsy.

Authors:  K Tawana; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

4.  In vivo covalent cross-linking of cellular actin by the Vibrio cholerae RTX toxin.

Authors:  K J Fullner; J J Mekalanos
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

5.  Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains.

Authors:  Ji Zhang; Suqing Wang; Wei Huang; David A Bennett; Dennis W Dickson; Dengshun Wang; Rui Wang
Journal:  Mol Neurobiol       Date:  2015-09-19       Impact factor: 5.590

6.  D-Ribosylated Tau forms globular aggregates with high cytotoxicity.

Authors:  Lan Chen; Yan Wei; Xueqing Wang; Rongqiao He
Journal:  Cell Mol Life Sci       Date:  2009-06-11       Impact factor: 9.261

7.  Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 8.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

9.  Characteristic fragment ions associated with dansyl cadaverine and biotin cadaverine adducts on glutamine.

Authors:  Kevser Biberoglu; Lawrence M Schopfer; Ozden Tacal; Oksana Lockridge
Journal:  Anal Biochem       Date:  2020-04-23       Impact factor: 3.365

10.  Heparan sulfate and transglutaminase activity are required for the formation of covalently cross-linked hedgehog oligomers.

Authors:  Tabea Dierker; Rita Dreier; Manuel Migone; Sabine Hamer; Kay Grobe
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.